



CME Digest

WHICH PATIENTS NEED AGGRESSIVE LIPID-ALTERING THERAPY?

Patients with some manifestation of coronary artery disease (CAD) are generally at five to seven times the risk for subsequent events compared with the general population. These manifestations include angiographic evidence of CAD or a history of myocardial infarction, coronary artery bypass grafting (CABG), or percutaneous transluminal coronary angioplasty (PTCA).

There should be no disagreement about the need for aggressive management of these patients. Preliminary evidence suggests that lipid therapy may reduce health care costs and is associated with a lower total mortality, lower mortality from coronary heart disease (CHD), and fewer CHD-related events of all types except restenosis after PTCA. The overall goal of drug therapy is to reduce CHD-related events and total mortality.

WHO IS AT HIGHEST RISK?

Patients with a history of thrombotic stroke or transient ischemic attack have four to six times the risk for CHD-related events. Preliminary data from several studies indicate that evidence of carotid artery stenosis on ultrasound is associated with increased risk for CHD. There is also preliminary evidence that lipid-lowering therapy reduces the risk of CHD-related events and slows disease progression in the carotid artery. Thus, patients with cerebrovascular disease are good candidates for aggressive lipid therapy.

Patients with intermittent claudication or prior intervention for arteriosclerosis obliterans have four

to six times the risk for CHD-related events. While not as well accepted, epidemiologic studies suggest that an ankle-brachial index of <0.85 also dramatically increases CHD risk. Again, therapy is definitely indicated to reduce CHD risk. There is only preliminary evidence for a reduced risk of progression in these arteries, and it will probably be several years until we have definite information.

GOALS OF LIPID-ALTERING THERAPY

The current priorities for lipid-altering therapy in patients with definite atherosclerotic vascular disease are as follows:

First, reduce low-density lipoprotein cholesterol (LDL-C) levels. Initiate dietary modification when the LDL-C level is >100 mg/dL (target level <100 mg/dL). If after an adequate trial of diet and life-style modifications the LDL-C level remains ≥ 130 mg/dL, drug therapy is indicated, and should be considered for LDL-C levels of 100 to 129 mg/dL.

Second, increase high-density lipoprotein cholesterol (HDL-C) levels as much as possible without drugs. Also consider drug therapy that controls both LDL-C and HDL-C levels.

Third, reduce triglyceride levels, using the recommended target of <200 mg/dL. Some suggest <150 mg/dL, but <200 mg/dL is more appropriate in the absence of definitive intervention trial data. Lower triglyceride levels are probably indicated in patients with diabetes mellitus.

TREATMENT SCENARIOS

As already stated, diet and life-style modification is indicated in all patients with established CAD and includes weight loss, exercise, smoking cessation,

and control of other risk factors.

However, diet and life-style modification often may not be sufficient to attain the goals mentioned above, and pharmacotherapy may be required. The following are four scenarios for the use of lipid-altering drug therapy.

1. *Elevated LDL-C, triglyceride levels <200 mg/dL.* Use a hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitor ("statin" drug), equivalent to 20 to 40 mg of lovastatin or pravastatin or 10 to 20 mg of simvastatin). Then consider combination therapy: add a bile-acid sequestrant to lower the LDL-C and consider niacin to increase the HDL-C.

2. *Elevated LDL-C, triglyceride levels 200 to 400 mg/dL.* Use niacin, but with the understanding that patients frequently do not tolerate an adequate dose. Statin drugs may not control HDL-C and triglycerides in these cases. Combination therapy is generally indicated: eg, a statin drug plus niacin, or a statin drug plus gemfibrozil. These regimens carry an increased risk of myopathy, especially when a statin is combined with gemfibrozil. Pravastatin may be less likely to cause myopathy. These patients are at very high risk, so referral may be appropriate if you do not feel comfortable with combination therapy.

3. *Triglyceride levels >400 mg/dL.* Use gemfibrozil or niacin. After triglycerides are lowered you may need to control the LDL-C.

4. *HDL-C <35 mg/dL, LDL-C <130 mg/dL, triglycerides <200 mg/dL.* Use niacin or statin. Gemfibrozil produces about the same increase in HDL-C as the statins. Statins are more effective in lowering LDL-C.

Most patients with established atherosclerotic vascular disease are candidates for drug therapy. Future studies will define the need for additional drugs, such as antioxidants. The role of hormone replacement therapy is also being defined. Many postmenopausal women with established disease may be candidates for this treatment.

DONALD B. HUNNINGHAKE, MD
Director
Heart Disease Prevention Clinic
University of Minnesota
Minneapolis

SUGGESTED READING

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National

Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. *JAMA* 1993; 269:3015—3023.

Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. *Am J Cardiol* 1991; 67:1186—1189.

Hunninghake DB. Drug treatment of dyslipoproteinemia. *Endocrinol Metab* 1990; 19:345—360.

Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. *Ann Intern Med* 1992; 117:1016-1037.

RHEUMATIC MANIFESTATIONS OF HIV INFECTION

In patients infected with the human immunodeficiency virus (HIV), the development of rheumatic conditions—including Reiter's syndrome, psoriatic arthritis, HIV-associated arthritis, myopathy, and Sjögren's syndrome—show that, besides inducing a state of immune deficiency, HIV also leads to a state of profound immunodysregulation. Treatment of these diseases is problematic, given that many of the standard therapies are themselves immunosuppressive. But the occurrence of rheumatic diseases among HIV-infected patients may provide added insight into the pathogenesis of clinical rheumatic diseases.

The association of rheumatic disease with HIV infection means that physicians need to take candid, nonjudgmental histories for HIV-associated risk behavior in all new patients. Physicians, especially those whose practice does not include many HIV patients, need to be aware of the signs and symptoms of HIV infection, including unexplained weight loss, diarrhea, fatigue, cutaneous herpes zoster, and lymphadenopathy. Physical signs that may appear include thrush, hairy leukoplakia, and cutaneous fungal infections.

For physicians who treat a large number of HIV patients, recognition of rheumatic conditions is both challenging and important. For example, the aches and pains of spondyloarthropathy may be confused with peripheral neuropathy. Conditions such as HIV-associated myopathy may be difficult to recognize. The design of aggressive therapies for both the underlying HIV infection and the clinical rheumatic state needs further development.

Interestingly, not a single case of classic rheumatoid arthritis has been reported to develop during an